BRUSSELS, Belgium, Dec. 9, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company is addressing an international gathering of pandemic influenza vaccine experts and potential commercial partners to encourage broader use of the company's DNA vaccine technology and Vaxfectin(R) adjuvant. Larry R. Smith, Ph.D., Vical's Vice President of Vaccine Research, presented today at the World Influenza Congress Europe (Brussels -- December 7-9), an innovative forum for the discussion of influenza policy and planning, vaccine research and development, and commercialization opportunities.
